VA
VR Adviser Portfolio holdings
AUM
$1.33B
This Quarter Return
+81.16%
1 Year Return
+6.92%
3 Year Return
+862.77%
5 Year Return
+1,580.48%
10 Year Return
–
AUM
$2.1B
AUM Growth
+$2.1B
(+44%)
Cap. Flow
-$50.4M
Cap. Flow
% of AUM
-2.4%
Top 10 Holdings %
Top 10 Hldgs %
63.64%
Holding
44
New
8
Increased
14
Reduced
7
Closed
6
Top Buys
| 1 |
Ocular Therapeutix
OCUL
|
$45.4M |
| 2 |
enGene Holdings
ENGN
|
$43.5M |
| 3 |
Dianthus Therapeutics
DNTH
|
$35M |
| 4 |
Edgewise Therapeutics
EWTX
|
$33.2M |
| 5 |
4D Molecular Therapeutics
FDMT
|
$31.1M |
Top Sells
| 1 |
RYZB
RayzeBio, Inc. Common Stock
RYZB
|
$251M |
| 2 |
Adverum Biotechnologies
ADVM
|
$50.8M |
| 3 |
AMAM
Ambrx Biopharma, Inc. Common Stock
AMAM
|
$29.5M |
| 4 |
Rhythm Pharmaceuticals
RYTM
|
$22.8M |
| 5 |
Celcuity
CELC
|
$19.8M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Apogee Therapeutics
APGE
$2.17B
| $564M | 26.85% | 8,493,321 | – | – |
|
|
2
4D Molecular Therapeutics
FDMT
$288M
| $140M | 6.67% | 4,400,000 +975,969 | +29% | +$31.1M |
|
|
3
Ocular Therapeutix
OCUL
$2.12B
| $116M | 5.52% | 12,762,462 +4,986,702 | +64% | +$45.4M |
|
4
Spyre Therapeutics
SYRE
$996M
| $82.4M | 3.92% | 2,171,782 -200,932 | -8% | -$7.62M |
|
5
Merus
MRUS
$4.98B
| $80.6M | 3.83% | 1,790,214 -358,000 | -17% | -$16.1M |
|
6
Pharvaris
PHVS
$1.39B
| $78.5M | 3.73% | 3,395,606 | – | – |
|
7
KalVista Pharmaceuticals
KALV
$678M
| $74.1M | 3.53% | 6,249,731 +2,157,000 | +53% | +$25.6M |
|
8
Enliven Therapeutics
ELVN
$1.2B
| $70.8M | 3.37% | 4,026,331 +1,071,429 | +36% | +$18.8M |
|
9
Viridian Therapeutics
VRDN
$1.5B
| $68M | 3.23% | 3,882,671 +48 | +0% | +$840 |
|
|
10
Dianthus Therapeutics
DNTH
$759M
| $62.8M | 2.99% | 2,094,373 +1,166,667 | +126% | +$35M |
|
11
Dyne Therapeutics
DYN
$1.92B
| $61.7M | 2.94% | 2,173,913 | – | – |
|
12
Applied Therapeutics
APLT
$71M
| $61.7M | 2.94% | 9,075,000 +2,825,000 | +45% | +$19.2M |
|
13
Oric Pharmaceuticals
ORIC
$994M
| $60.4M | 2.87% | 4,394,527 +1,966,142 | +81% | +$27M |
|
14
Astria Therapeutics
ATXS
$349M
| $50.8M | 2.42% | 3,608,645 +382,839 | +12% | +$5.39M |
|
15
Mersana Therapeutics
MRSN
$36.5M
| $50.7M | 2.41% | 11,328,000 | – | – |
|
|
16
enGene Holdings
ENGN
$236M
| $43.5M | 2.07% | +2,565,841 | New | +$43.5M |
|
17
Praxis Precision Medicines
PRAX
$958M
| $43.1M | 2.05% | 706,126 +352,500 | +100% | +$21.5M |
|
18
HilleVax
HLVX
$105M
| $34.5M | 1.64% | 2,075,000 | – | – |
|
19
Cogent Biosciences
COGT
$1.69B
| $34.5M | 1.64% | 5,129,167 +445,000 | +10% | +$2.99M |
|
|
20
Edgewise Therapeutics
EWTX
$1.51B
| $33.2M | 1.58% | +1,818,182 | New | +$33.2M |
|
21
Cabaletta Bio
CABA
$133M
| $26.7M | 1.27% | 1,563,952 -1,000,000 | -39% | -$17.1M |
|
22
Arvinas
ARVN
$568M
| $25.9M | 1.23% | 627,788 | – | – |
|
23
Taysha Gene Therapies
TSHA
$797M
| $25.8M | 1.23% | 9,000,000 -1,412,872 | -14% | -$4.05M |
|
24
Aquestive Therapeutics
AQST
$456M
| $23.7M | 1.13% | +5,555,555 | New | +$23.7M |
|
25
Terns Pharmaceuticals
TERN
$609M
| $22.4M | 1.06% | 3,410,058 -1,087,059 | -24% | -$7.13M |
|